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In Myotonic Dystrophy type 1 (DM1), the accumulation of transcripts containing CUG triplet 
expansions leads to the dysregulation of multiple cellular processes, including RNA splicing and 
microRNA (miRNAs) synthesis. This project aims to find functional miRNAs that are specifically 
deregulated in muscles of DM1 patients, and to identify circulating miRNAs in the plasma of DM1 
patients that could be used as biomarkers of DM1 disease progression. Preliminary studies had 
previously identified a group of miRNAs that were deregulated in the plasma or serum of small groups 
of DM1 patients. In this work, very stringent selection and normalization criteria were adopted to 
validate or disprove these miRNAs in 103 DM1 patients and 111 matched controls. We found that 8 
miRNAs out of 12 were significantly deregulated in DM1 patients and that the levels of these 
miRNAs discriminated DM1 from controls significantly. Next, we determined a “DM1-miRNAs 
score”, calculated averaging the values of all 8 miRNAs, and a “miR-133a/b score” obtained 
averaging the levels of the two miR-133 members, both displaying a good ability to discriminate 
between DM1 and control subjects. Additionally, both scores correlated with muscle strength and 
Creatine Kinase levels. Moreover, 7 out of 8 miRNAs were found deregulated also in 30 patient 
affected by Myotonic Dystrophy type 2. The second aim of this work was the identification of 
miRNA/target mRNAs couples deregulated in skeletal muscles of DM1 patients. To this aim, the 
RNAs associated to RISC effector complex were analyzed from muscle biopsies of DM1 patients and 
healthy individuals and RNA-Sequencing was used to identify RISC-associated small RNAs 
(miRNAs) and long RNAs (mRNAs). A number of small and long RNAs differentially expressed in 
RISC complexes of DM1 vs healthy controls were identified, that showed statistically significant 
modulation. Next, using target prediction algorithms, miRNA-mRNA couples deregulated in DM1 
were identified. RNA-sequencing data confirmed in independent qPCR assays, analyzing larger 
groups of DM1 patients and controls. Moreover, using myogenic cell models derived from dermal 
fibroblasts of DM1 patients and healthy individuals, a subset of these interactions was confirmed, 
validating this in vitro system for future functional studies. 
In conclusion, this study identified relevant tissue miRNAs aberrantly expressed in DM1 and 
validated plasma miRNAs as potential DM1 biomarkers. 
Abbreviations list. 
DM = Myotonic dystrophy; CTR = control; CDM = congenital myotonic dystrophy; 3’UTR = 3’ untranslated region; TP- 
PCR= triplet-repeat primed PCR; FISH = fluorescent in situ hybridization; IP= immunoprecipitations; RISC = RNA-
induced silencing complex; MIRS= muscular impairment rating scale; MRC scale= medical research council scale; AUC 





II.I. MYOTONIC DYSTROPHIES 
 
Myotonic dystrophies (DM) are autosomal dominant, multisystemic disorders sharing many 
clinical characteristics, including myotonia, progressive muscle weakness, heart conduction defects, 
posterior iridescent cataract and endocrine disorders 1,2. To date, two different forms have been 
characterized: Myotonic Dystrophy type 1 (DM1, OMIM: 160900), also known as Steinert’s disease, 
and Myotonic Dystrophy type 2 (DM2, OMIM: 602668), frequently indicated as Proximal Myotonic 
Myopathy (PROMM) or Proximal Myotonic Dystrophy (PDM). 
 
Epidemiology of DM 
DM1 prevalence estimates in Europe range from 1 in 8.300 to 1 in 10.700 3, while studies 
performed on non-European populations indicate that DM1 is highly prevalent in certain founder 
populations like the one of Northeastern Quebec, where the frequency reaches 1 in 500 4,5. Prevalence 
of DM2 is thought to be underestimated, due to milder and ambiguous symptoms characterizing 
patients. Nevertheless, it is estimated to be similar to DM1 in European populations 6. 
 
DM are repeated expansion diseases 
DM1 is caused by (CTG)n expansions in the 3’ untranslated region (UTR) of DMPK (myotonic 
dystrophy protein kinase) gene, which encodes for a myosin kinase ubiquitously expressed, but 
particularly relevant in skeletal muscle 2. In the general population, CTG repeats range from 5 to 37 
repeats, while DM1 patients present at least 50 and up to 4000 CTG repeats 7. A mutation length of 
more than 2000 repeats causes the congenital form (CDM) 8, the most severe form of the disease, 
absent in DM2, with fetal onset and involvement of the central nervous system 9. 
DM2 patients present (CCTG)n tetraplet repetitions in the first intron of the CNBP (nucleic acid-
binding protein) gene 10. The number of tetraplets is > 1000 in more than 90% of patients 5, while in 
healthy individuals the repeats are below 30 11. 
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Both DM1 and DM2 mutations are characterized by high instability, leading to the so called 
“somatic mosaicism”, due to the fact that certain tissues display a higher tendency to extend these 
tandem repeat sequences than others. As expected, the longest repeats are present in severely affected 
tissues: indeed, skeletal muscle cells possess considerably longer repeats than other cell types 1. The 
genetic instability is also present in germline cells, which accumulate tandem repeats. Accordingly, 
DM is characterized by the genetic phenomenon of anticipation, so that symptoms begin at an earlier 
age in successive generations, especially in DM1 12,13. The congenital form of DM1 is almost always 
inherited by the mother 14; however, anticipation may be also seen in patients with DM1 who inherited 
a smaller expanded CTG repeat from their father 15. Finally, in DM2, there is the unusual tendency 
of repeats to be shorter in the offspring after both maternal and paternal transmission, with an increase 
in repeats size with age 16. 
 
Clinical aspects 
In DM1, distal skeletal muscles are generally more compromised, and the most severe type of 
DM1 is the CDM, which present a distinct clinical phenotype, in most cases even before birth. 
Respiratory failure is the main cause of post-natal death, but surviving babies present a gradual 
improvement in motor functions, and almost all CDM children are able to walk 2. In the adult form 
of DM1, symptoms usually develop in the second, third or fourth decade 5 and distal muscle 
weakness, cataracts, myotonia, cardiac involvement and endocrine abnormalities are present in high 
percentage, with different grades 5,11. Moreover, DM1 patients go through behavioral-personality 
changes (e.g., inactivity, apathic temperament and paranoid personality traits) and excessive daytime 
sleepiness 1. 
Symptoms are generally milder in DM2 than in DM1, and usually begin in the second to sixth 
decade 16, selectively affecting the proximal muscles (limb girdle, neck flexor, and elbow extensor 
muscles) 5. Myotonia is often less apparent in DM2 compared to DM1 11, the cataracts have an 
appearance identical to that observed in DM1, and cardiac defects, like conduction abnormalities and 
arrhythmia, appear to be less severe and frequent in DM2 compared to DM1 17.  
DM patients seem to display higher risk of cancer, most frequently involving thyroid gland, ovary, 
colon, endometrium, brain, and eye (choriodal melanoma) 5,18,19, and very recently, it has been found 
that cancer risk seems to be sex-related, with a higher prevalence in DM1 females 20. 
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Furthermore, DM1 is frequently associated to metabolic dysfunctions, with insulin resistance, 
increased cholesterol and hypertriglyceridemia 21 and patients may also suffer of fertility dysfunction. 
Approximately two thirds of the affected males have reduced sperm quality as a result of testicular 
atrophy 22, while infertility in DM women is still debated 23, even if it was found that, especially in 
DM1, there is a reduced ovarian reserve, decreased embryo quality and lower live birth rates 24.  
 
Mechanism of pathogenesis 
For both DM1 and DM2, the expanded repetitions are present in non-coding sequences and both 
disorders result from toxicity of repetitive RNAs 25 with the mechanism of “toxic RNA gain-of-
function” 26. 
In DM1, the mutation is located near the site of polyadenylation but, even when the number of 
repeats is very high, it does not interfere with the processing of DMPK mRNA 5,26, which normally 
is spliced and polyadenylated. However, its nuclear sequestration in characteristic foci prevents 
translation. 
A similar mechanism is involved in DM2 pathogenesis, where the transcribed but not translated 
CCUG in the first intron of the CNBP gene, leads to nuclear sequestration of the mRNA 27.  
DMPK and CNBP mRNAs nuclear retention results in the sequestration of MBNL1 (Muscleblind-
1) protein, which is one of the master regulators of the alternative splicing process 28, leading aberrant 
alternative splicing events of several transcripts 27. Nuclear sequestration of mutated RNAs and their 
association to MBNL1 are easily detectable as foci 29 by fluorescent in situ hybridization (FISH) 30. 
DMPK is a serine-threnonine kinase, whose role in skeletal muscle tissue is not yet well 
understood. It is associated to the nuclear envelope and its deficiency can cause nuclear envelope 
instability 31. Harmon and colleagues also found that DMPK depletion reduces myogenin expression 
and prevents myotubes formation 32; another study identified DMPK to be involved in the 
phosphorylation of the myosin-binding subunit of myosin phosphatase (MYPT1), which inhibits 
myosin phosphatase (PP1c) activity 1,33. CNBP gene, on the other hand, is a nucleic acid binding 
protein which specifically binds to RNA and DNA, modulating the transcription of some genes 
involved in Wnt signaling 34, an important regulator of skeletal muscle development 35. 
Despite the biological relevance of these genes, their haploinsufficency seems to be not the primary 
pathogenetic of DM. In fact, DMPK knockout mice do not reproduce the multisystemic phenotype 
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of DM1, and develop late-onset myopathy 36,37. Regarding CNBP haploinsufficiency there are 
contrasting results: indeed, one study showed that CNBP +/- mice develop multisystemic features, 
like muscle wasting, cataracts and heart conduction defects 38; however, another work showed that 
that CCTG expansion do not influence CNBP protein levels, dismissing decreased CNBP levels as 
pathogenetic mechanism 39. 
MBNL1 is a part of a conserved protein family, composed by MBNL1, 2 and 3. All three members 
contain four CCCH zinc-finger protein domains, that are structured in pairs and function as RNA-
binding domains 28. MBNL proteins in normal cells act as alternative splicing regulators of several 
hundred transcripts 40 and they also have a role in regulating RNA transport and decay 41. One of the 
MBNL1 characteristics is the high affinity with CUG repeats. This feature, in addition to mutated 
RNAs present in DM, leads to sequestration of MBNL1 into cell nuclei and to the misregulation of 
several splicing events 41. In addition, the lack of MBNL1 bioavailability increases the activation of 
CUGBP1 (CUG binding protein 1), another splicing factor, which is more active in fetal life 26 
(Figure1) These alterations lead to the maturation of fetal mRNA isoforms in DM adult tissues 42,43, 
potentially explaining many different symptoms present in DM. For example, the mis-splicing of 
ClC-1 (Chloride channel 1) correlates to reduced chloride conductance in skeletal muscle fibers, 
producing myotonia 44, while defects in the insulin receptor (IR) are associated to insulin resistance, 
frequently present in DM patients 45. Several analyses of alternative splicing changes have been 
performed, also by our group 46–48, Indeed, the identification of aberrant splicing events not only can 
shed light on the disease mechanisms, but is also of potential prognostic use, since some events are 
present even before the appearance of symptoms 47. 
Given the mounting evidence indicating splicing aberrations as a central disease mechanism, DM 
is often indicated as a “spliceopathy”. 
While aberrant alternative splicing is considered as the most plausible disease cause of DM, 
alternative mechanism have been proposed. Indeed, in 2010, Zu and colleagues discovered that in 
DM1, expansion mutations can drive the expression of proteins without an AUG initiation codon 49, 
and this novel type of translation was called repeat associated non-ATG (RAN) translation. 
Specifically, because DM1 mutation is bidirectionally 49, RAN translation of the DMPK antisense 
transcript gives rise to homopolymeric polyglutamine (poly[Q]n) peptides in patients’ cells, including 
skeletal muscle cells, and in mouse models of DM150.  
Moreover, double-stranded (CUG)n hairpins are recognized by PKR (dsRNA-activated protein 
kinase) activating several cellular stress pathways, which finally lead to a global inhibition of 
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translation 51. Accordingly, a significant reduction of protein synthesis has been reported both in DM1 
and DM2 muscles, suggesting a functional link between reduced protein translation and muscle 
wasting 52,53. Indeed, prolonged activation of PKR leads to stress in the endoplasmic reticulum, which 
could results in a block of translation initiation or apoptosis, both of which can lead to muscle wasting 
and weakness 50. 
 
 
Diagnosis and treatment 
As for all genetic diseases with known mutations, also for DM1 and DM2 the typical diagnostic 
method is the genetic test. For DM1, PCR analysis is used to detect repeat lengths less than 100 and 
Southern blot analysis to detect larger expansions 2. Triplet-repeat primed PCR (TP-PCR) 54 is also 
considered a routine diagnostic procedure, since it represents a robust and precise PCR method, but 
the association of two molecular methods such as Long-PCR and Southern transfer, together with 
TP-PCR 55,56, is strongly recommended to detect a wide range of mutations 2. These analyses can be 
Figure 1. Pathogenetic mechanism in DM1 and DM2 Modified from151 
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performed using genomic DNA extracted from the peripheral blood, minimizing the invasiveness of 
the test. 
For DM2, the presence of a wide variability in the clinical spectrum, makes the diagnosis more 
difficult. Furthermore, Southern blot and conventional PCR analysis are not suitable for a definitive 
genetic diagnosis, because of the extremely large size and somatic instability of the expansion 
mutation 10,57. So, a more invasive, but conclusive method to obtain a DM2 diagnosis is represented 
by in situ hybridization (ISH), which is a method allowing the visualization of the mutant RNA in 
muscle tissues 58,59. By using specific probes for CCUG expansions, it also permits a differential 
diagnosis between DM1 and DM2, 58,59. Moreover, since MBNL1 is sequestered by mutant RNA 
foci, it is possible to visualize the nuclear accumulation of MBNL1 by FISH on muscle sections 2, 
even if it cannot distinguish between DM1 and DM2. 
To date, no specific treatments are available for DM. Anti-myotonia therapy is helpful, and usually 
it consists in mexiletine or carbamazepine 2; placement of a pacemaker or of a cardiac defibrillator 
can be lifesaving, especially in DM1 5. In general, the management of DM is based on preserving 





II.II. MicroRNAs IN TISSUES AND BODY FLUIDS 
 
Biogenesis and function of microRNAs 
MicroRNAs (miRNAs) are short (~23 nucleotides) non-coding RNAs, that play important gene 
regulatory roles in animals and plants by pairing to mRNA targets to lead their post-transcriptional 
repression. They are involved in virtually all biological process, including development, 
differentiation, stress response, apoptosis and proliferation 60.  
The number of human miRNAs described to date has exceeded 2500, continuing to increase, and 
it is estimated that miRNAs regulate the expression of more 60% of protein-coding genes 61. miRNA 
genes can be placed in independent transcription units or could be found in the introns of protein 
coding genes, and sometimes in exons of protein coding genes 62. They are transcribed by RNA 
polymerase II, producing long capped and polyadenylated precursors called primary miRNAs (pri-
miRNAs) 63,64. The pri-miRNA contains a hairpin, of ∼70 nt (pre-miRNA), and the pre-miRNA, in 
turn, contains the sequence of the mature miRNA. Pre-miRNAs are processed by RNase III Drosha, 
in complex with the RNA-binding protein DGCR8 65, and then exported by Exportin 5 to the 
cytoplasm 66, where it is further processed by RNase III Dicer in complex with the RNA-binding 
protein TRBP. 
The resulting double stranded molecule of 22-23 nt associates to a protein of the Ago (Argonaute) 
family, which is the main component of the protein effector complex known as RISC (RNA-induced 
silencing complex). One of the strands of the duplex usually gets degraded, while the mature miRNA 
(guide strand) associates to the RISC complex, interacting with target mRNAs. The mechanism by 
which miRNA sequence complementarity drives the functional regulation of mRNA targets has been 
deeply investigated, finding that the miRNA 5′ region from nucleotide 2 to 8 (known as the ‘seed’ 
region) is of particular importance in targeting 67. The seed region is the most evolutionarily 
conserved sequence of miRNAs 68 and its complementarity regions are more frequently found in the 
3’UTR (3’-untranslated region) of the target mRNAs 69. However, target sites in the 5’UTR (5’-
untranslated region) or the coding region 70,71 are not uncommon.  
In spite of intense research, the mechanisms through which miRNAs regulate gene expression 
remain unclear and have been subject of many controversies over the past few years. Indeed, evidence 
for both translational repression and mRNA destabilization has been shown 72. First studies in animal 
cells pointed to regulation by miRNAs of mRNA translation. Translation in mammals requires many 
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factors allowing the recruitment of the ribosomal subunits to the mRNA initiation codon (initiation), 
the elongation of the nascent polypeptides (elongation) and the release of the mature protein 
(termination). Some of these factors recognize the 5' Cap or the 3' UTR of the mature mRNAs, 
allowing its efficient translation 73. Many studies showed miRNAs ability to inhibit mRNA translation 
initiation 74,75; however, elongation inhibition, premature termination of translation and co-
translational protein degradation have been described as well 72,76–79. While perfect pairing of a 
miRNA to its target, resulting in Ago2-dependent endonucleolitic cleavage, is seldom observed in 
animal cells, exonucleolitic degradation often occurs. miRNAs, promoting the recruitment of 
deadenylation factors to the target mRNA, stimulate the removal of mRNA poly-A tail, making it 
susceptible to exonucleolitic degradation. Indeed, binding of factors such as PAN2-PAN3 and CCR4-
NOT 80, promotes deadenylation to repress translational initiation 81,82.  
Many high throughput transcriptomic and proteomic studies all indicated that degradation of 
miRNA targets is a very common mechanism of miRNA action, providing a major contribution to 
target mRNA repression 60,72,83. However, whether or not target degradation occurs as a consequence 
of an initial block in translation remains as an open issue.  
 
There are also anecdotal reports of an activating role of the miRNAs: it has been described that 
they can cause an increase in mRNA translation (Vasudevan S., Tong Y. 2007). Moreover, 
epigenetically controlled transcriptional gene silencing has been identified as well 85.  
Due to their short length and partial complementarity to mRNAs, each miRNA can regulates 
hundreds of targets 86. On the other side, mRNAs usually have several binding sites for the same or 
different miRNAs, that provide a massive regulation of expression, which may be different in 
different cell types 87.  
Indeed, each cell type has its specific miRNA expression profile, even if most miRNAs are 
expressed in several tissues, and only some of them have tissue-specific expression 88.  
It is known that, for instance, miR-122 is typical of the liver 89, miR-126 is particularly enriched 
in the lung 90, miR-223 and miR-146a are more expressed in the spleen 90 and, finally, miR-1,-133a,-
133b,-206, -208b, -486, -499 denote preferentially skeletal muscle and myocardial tissues, for this 
reason, they are indicated also as myomiRs 91,92. These tissue specific miRNAs could play a role in 




miRNAs in skeletal muscles 
The potential of using miRNAs profiles for classification of skeletal muscle pathologies has been 
elegantly demonstrated by Kunkel's group, who identified distinct patterns of miRNAs in muscle 
biopsies derived from 10 major neuromuscular disorders 93. We and others found that in DM1 
muscles, miR-206, miR-1 and miR-335 are over-expressed, whereas miR-29b, miR-29c and miR-33 
are down-regulated. However, independent studies have found either no changes in miR-1 levels or 
a reduction of this miRNA, due to defective maturation of the precursor 94–96. In addition to miR-1, 
also miR-7 and miR-10 have been found downregulated in a DM1 Drosophila model as well as in 
DM1 patient-derived cells 94. Importantly, we also found that miR-1, miR-133b and miR-206 
myomiR intracellular distribution was severely altered 96.  
Very recently, our group performed a study about skeletal myogenesis in mouse satellite cells, 
using in silico miRNA target prediction together with biochemical pull down techniques in order to 
obtain immunoprecipitates (IPs) of RISC complexes 97. This approach, associated to RNA 
sequencing, have underlined the great importance of miR-222 in skeletal muscle differentiation; in 
particular, a new function of miRNA-222, leading to alteration of myogenesis at the level of the 
alternative splicing by Rbm24, was discovered 97. Indeed, the RNA binding protein Rbm24 is a major 
regulator of muscle specific alternative splicing, and its down regulation by miRNA-222 resulted in 
defective exon inclusion, impairing the muscle-specific isoforms of Coro6 (Coronin), Fxr1(FMR1 
autosomal homolog 1) and NACA (nascent polypeptide-associated complex alpha subunit 
transcripts) 97.  
This study further underlines that, searching for “functional” miRNAs in muscle biopsies, i.e. of 
miRNA species actually associated to RISC complexes and engaged in mRNA targets 
downregulation, is of crucial importance to really understand the role of miRNAs in the pathogenetic 
process of skeletal muscle disorders. 
 
Circulating miRNAs 
miRNAs have been detected in most biological fluids, including plasma, serum, milk, tears, saliva, 
urine, amniotic, cerebrospinal and semen fluids 87. These miRNAs are surprisingly very stable, 
showing distinct expression profiles among different fluids. 
It is known that serum and other body fluids are rich in ribonucleases 98, but circulating miRNAs 
result to be very stable, because they are protected from degradation by the association with lipid 
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vescicles, with RNA-binding proteins 99, with high-density lipoproteins (HDL) or with Ago proteins 
100,101 (Figure 2).  
 
Despite the growing number of evidence for the presence of miRNAs in body fluids, the origin 
and especially the function of these extracellular miRNAs are still poorly understood. Even if the 
presence of circulating miRNAs is probably a result of a combination between active and passive 
release by the cells, it is now clear that they have many characteristics to be good potential 
biomarkers. Moreover, given their specificity, another interesting possibility is to use circulating 
miRNA levels to monitor the physiopathological conditions of a specific organ 99.  
The changes in circulating miRNA levels have been studied for several diseases, in different body 
fluids. For example, serum levels of miR-141 is able to discriminate between patients with advanced 
prostate cancer and healthy individuals 102, while miR-1, -133a/b, -208b and miR-499 are elevated in 
myocardial infarction and correlate with troponin plasma levels 103,104. Moreover, circulating 
miRNAs were also found deregulated in muscular dystrophies: indeed, levels of muscle-specific 
miRNAs (myomiRs), like miR-1, -133a/b, -206 have been found altered in the blood of both mice 
and humans affected by Duchenne muscular dystrophy 105,106. 
Figure 2. Circulating miRNAs 152 
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Very recently, two independent studies have identified plasma/serum circulating miRNA levels 
altered in small groups of DM1 patients 107,108. In particular, the study of our group was conducted on 
plasma derived from 36 DM1 and 36 healthy subjects, finding 8 miRNAs (miR-133a, -193b, -191, -
140-3p, -454, -574, -885-5p) increased and only 1 (miR-27b) decreased in DM1 108. Moreover, both 
miR-133a alone or the entire miRNA signature display an inverse correlation with muscle strength 
and show higher values present in more compromised patients 108. In the study of Koutsoulidou et al., 
serum myomiRs (miR-1, -133a,-133b,-206) were found up-regulated in 23 DM1 and correlated to 
disease progression 107. 
Biomarkers are critically important for disease diagnosis and monitoring. In particular, close 
monitoring of disease evolution is eminently required for the evaluation of therapeutic treatments. 
The ability to indicate the state of an organism, combined with high stability, make circulating 
miRNAs suitable markers allowing non-invasive and highly specificity diagnostics. This could help 
not only to save time and money, but also to be more accurate than using the existing markers 109.  
Nevertheless, there are some issues which need to be resolved, in order to create standardized and 
reproducible procedures in the quantification of circulating miRNAs. One of the main problem is 
that, especially for rare diseases such as DM, most studies lack power because of small size of the 
patient groups analyzed. This limitation, associated to the great challenge in finding a robust 
normalization method, frequently lead to conflicting or not reproducible results.  
 
Therapeutic modulation of miRNAs 
Antisense Oligonucleotides (ASO) are the most used technology for inhibiting miRNAs. In 
particular, the use of Locked Nucleic Acid (LNA)-modified oligonucleotides is very frequent in in 
vitro and in vivo studies, given the high bio-stability, the low toxicity and good bio-distribution 110. 
As previously mentioned, miR-122 is highly abundant in liver, and it has been demonstrated to be 
required for HCV (hepatitis C virus) replication 111, which is the major cause of hepatocellular 
carcinoma (HCC) in humans 111.  
It has been found that, in chronically infected chimpanzee, the usage of LNA-anti-miR-122 
reduced more than 300 fold the HCV levels in sera of animals treated with LNAs 112. These results 
lead to consider miRNAs as efficient therapeutic targets also in humans, and a clinical trial on HCV 
infected patients with anti-miR-122 treatments (Miravirsen) successfully completed phase 2 63. These 
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results provide perspectives on the future of miRNA-based therapeutics for many other diseases, like 






II.III. AIMS OF THE PROJECT 
In the last decades, research on miRNAs have highlighted that their fine mechanism of post 
transcriptional regulation is fundamental in almost all cellular processes. They are present not only in 
tissues, but also in biological fluids, as a result of active and passive releasing from different cells. 
These characteristics made miRNAs both good potential biomarkers and therapeutics targets for 
many different diseases. Moreover, a growing number of evidence shows that miRNAs are deeply 
involved in the skeletal muscle physiological and pathological conditions, particularly in muscular 
dystrophies, including DM. 
The aim of my PhD project is understanding the role of microRNAs dysregulation in DM1 and the 
development of a DM1-specific circulating miRNA signature to use as disease biomarker.  
In particular, the project is focused on two main points: 
-validation in a large patient cohort of a DM1 plasma signature to use as biomarkers of disease 
staging/severity; 
-investigating the dysregulation of miRNAs association to RISC complex in muscle biopsies derived 





III. MATERIALS AND METHODS 
 
Patients’ selection and samples collection 
This study was authorized by the Institutional Ethics Committees and was conducted according to the 
principles expressed in the Declaration of Helsinki, the institutional regulation and Italian laws and 
guidelines. All blood samples and skeletal muscle biopsies were taken after specific written informed 
consent.  
Clinical diagnosis of DM1 and DM2 patients was based upon International Consortium for Myotonic 
Dystrophies guidelines 6 and genetic analysis was carried out to confirm DM1 113 and DM2 diagnosis 
56.  
Stage of disease was determined using Muscular Impairment Rating Scale (MIRS) 114 1 = no muscular 
impairment, 2 = minimal signs, 3 = distal weakness, 4 = mild–moderate proximal weakness, 5 = 
severe proximal weakness. Five-point MRC scale (Medical Research Council) in the upper and lower 
limbs for a total maximum score of 150 (MRC megascore) was used to evaluate muscle strength 115. 
Specifically, the score was obtained measuring on both sides 7 muscle groups of the upper limbs 
(shoulder abductors and adductors, elbow flexors and extensors, wrist flexors and extensors, finger 
flexors) and 7 muscle groups of the lower limbs (hip flexors and extensors, knee flexors and extensors, 
ankle dorsiflexors and plantar flexors, extensor hallucis) as well as neck flexors and extensors. 
Myotonia was evaluated qualitatively during neurological examination and confirmed by needle 
electromyography. 
Blood samples were obtained by venous punctures of 103 DM1 and 111 age and sex matched patients 
dysplaing no clinical signs of neuromuscular disorders (CTR) (Table 1). Moreover, 30 DM2 patients 
and 30 age and sex matched controls were also considered (Table 1). EDTA-tubes were used for 
samples preparation. Cell- and platelet-free plasma was prepared following a 2 step centrifugation 
protocol: samples were centrifuged at 1.500 g for 15′ at 4 °C. Next, the supernatant was centrifuged 
again at 14.000 g for 15′ at 4 °C and stored at −80 °C 108.  
Biceps brachii biopsies of 10 DM1 patients and 10 age and sex matched healthy subjects, were 
harvested under sterile conditions and snap-frozen in liquid nitrogen (DM1: 3 males, 7 female, 
49.0±1.9 years; CTR: 5 male, 5 female, 48.9±2.2 years). 
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Plasma RNA extraction 
Total RNA from plasma was extracted using NucleoSpin miRNA Plasma (Macherey-Nagel) as 
previously described 108. Pellets were re-suspended in 50 μl of RNAse-free water and samples were 
spiked-in with 25 fM of exogenous cel-miR-39 (Ambion) to assess the efficiency of RNA extraction, 
because Nanodrop (Thermo Scientific) quantification was not reliable, due to the low amount of 
extracted material. 
Hemolysis was tested measuring plasma absorbance at 570 and 600 nm wavelengths, where oxy-, 
deoxy- and carboxy-hemoglobin display similar absorbance 116. 
 
Plasma miRNAs quantification and scores calculation 
RNA was retro-transcribed by Taqman microRNA RT kit (Life technologies), following 
manufacturer’s instructions, and miRNAs were measured by qPCR using TaqMan microRNA assays 
(Life technologies), performed in duplicate. Relative expression was calculated using the comparative 
Ct method 117. To calculate ∆Cts values, the average of 3 normalizers was used: spike in cel-miR-39 
and 2 endogenous stable miRNAs, miR-106a and miR-17-5p, as previously described 108. Next, to 
calculate ∆∆Ct values, DM1 and individual controls were all compared to a reference pool of all 
control RNAs (control mix), measured in quadruplicate, ensuring comparable results throughout the 
study. 
For the scores calculation, ΔΔCt values were converted to a linear scale, using the formula 2^(-ΔΔCt) 
to represent the up-regulations, while for the down-modulation, data were calculated as -2^(ΔΔCt). 
Subsequently, “DM1-miRNA score” was obtained by averaging the fold changes for all validated 
miRNAs, while for “myomiR score” and “miR-133a/b score”, the average of miR-1,-133a, -133b,-
206 or only miR-133a and -133b were used, respectively. 
 
Ago2 immunoprecipitation in skeletal muscle tissue and RNA extraction 
 Lysate preparation 
Biceps brachii biopsies were homogenized by Tissue Lyser (Quiagen) in RIP lysis buffer of Magna 
RIP™ RNA-binding protein Immunoprecipitation kit (Merck-Millipore, Billerica, MA, USA). In 
particular, 100 µl of complete lysis buffer was prepared for each sample, mixing 97 µl of RIP lysis 
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buffer, 0.5 µl of Protease cocktail inhibitor and 0.25 µl of RNAse inhibitor (Merck-Millipore). After 
homogenization and protein quantification, lysed samples were snap frozen in liquid nitrogen and 
stored at -80°C until use.  
 Preparation of magnetic beads 
To prepare the magnetic beads, 50µl of beads suspension was used for each sample and washed twice 
with 0.5 ml of RIP wash buffer, placing the tubes on a magnetic separator (MagnaRck™, Invitrogen). 
After the second washing, 5 µg of RIPAb+ Ago2, Monoclonal Anti-Ago2 (11A9,Sigma Aldrich) or 
Normal mouse IgG (Merck-Millipore) were added, in order to precipitate Ago2 protein or aspecific 
negative control for each homogenized sample, respectively. The beads were incubated with the 
antibodies for 30 min at room temperature (RT) on a TubeRotator (VWR®). After the incubation, the 
beads were separated on the magnetic rack and washed twice with 0.5 ml RIP wash buffer. 
 Immunoprecipitation 
A RIP immunoprecipitation buffer was prepared for each sample, mixing 860 µl of RIP wash buffer 
with 35 µl of 0.5M EDTA and 5 µl of RNAse inhibitor (Merck-Millipore). 
In each tube containing Ab-conjugated beads, the wash buffer was replaced by 900 µl of RIP 
immunoprecipitation buffer and frozen lysate was rapidly thawed and centrifuged ad 14.000 rpm for 
10 minutes at 4°C. After this step, 50 µg of lysate was used to extract “input RNA” and mixed with 
200µl of TRIzol® reagent (Invitrogen™), while the remaining material was divided in half between 
Ago2 and negative control assays. All the tubes were then incubated with rotation for 4 hours at 4°C, 
and then, the tubes were placed on the magnetic separator to perform five washes, with 0.5 ml of RIP 
wash buffer. After the last washing, the beads were separated on the magnetic rack, the supernatant 
discarded and 200µl of TRIzol® (Invitrogen™) was added to each sample. 
 RNA extraction 
Input and immunopurified (IP) samples harvested in TRIzol®, were let at RT for 2-3 minutes, then, 
after the addition of chloroform (40µl), were vortexed and centrifuged at 12000xg, at 4°C for 15 
minutes. Next, the aqueous phases were transferred into clean tubes, and 5µg of Glycogen (Roche) 
and 104µl of Isopropanol (SigmaAldrich) were added to each sample. Afterward, the RNAs were let 
to precipitate at 4°C up to 2 hours and then centrifuged at 12000xg for 10 minutes at 4°C.  
Pellets were washed two times with 1 ml of 80% ethanol (Sigma-Aldrich), centrifuged at 5000xg for 
5 minutes at 4°C and, after the last washing, pellets were let to dry and finally re-suspended in 10-15 
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µl of sterile water. In the samples to be processed for small RNAs sequencing, a spike in control small 
RNA (cel-miR-39, 25 fMol) was added during the extraction procedure to be used for normalization.  
 
Protein quantification 
The protein quantification was performed using the Pierce™ BCA Protein Assay kit (Thermo 
Scientific), which is based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantitation of total proteins. Standard curves were prepared using diluted albumin (BSA, 2mg/ml) 
standards and the absorbance at 562nm was measured by Victor3 Multilabel Plate Reader 
(PerkinElmer). 
 
RNA sequencing and gene ontology (GO) analysis 
RNA-Sequencing was used to measure small and long RNAs deriving from RISC-IP samples, while 
for total RNA, only small RNAs were sequenced. All total RNAs were checked for integrity (RIN) 
by Bioanalyzer (Agilent) according to manufacturer’s instructions, while RNAs derived from IPs 
were impossible and to check for integrity, given the very low amount of material. Previous 
experiments indicated that 50-100 ng RNA/skeletal muscle biopsy were recovered 
RNA sequencing was performed in collaboration with Dr. Jose M. Garcia-Manteiga (Center for 
Translational Genomics and Bioinformatics, S. Raffaele Institute, Milan-Italy), by Illumina next 
generation sequencing (NGS) platform HiSeq 2000. The RNA-seq of small RNAs included barcoded 
and pooling of samples in 4 pools containing both IP small RNAs and total small RNAs. Small RNA 
libraries were prepared using the TruSeq Small RNA Sample Preparation Kit (Illumina). The cDNA 
was then PCR amplified using specifically designed primers. This protocol takes advantage of the 
natural structure common to most known mature miRNAs having a 5'-phosphate and a 3'-hydroxyl 
group as a result of enzymatic cleavage by Dicer or other RNA processing. Because of this, the RNA 
adapters are ligated to each end of the RNA molecule and an RT reaction is used to create single 
stranded cDNA. 
mRNA libraries were generated with Ovation RNA-Seq System V2 (NuGen) which allows to prepare 
amplified cDNA starting from small total RNA amounts. Amplification was initiated at the 3' end as 
well as randomly throughout the whole transcriptome in the sample, allowing the amplification of 
both mRNA and non polyadenylated transcripts.  
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After trimming of sequencing adapters (trimmomatic), the sequences quality was checked with 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The alignment to the genome 
(hg19) was made with BWA (Burrows-Wheeler Aligner) 118 and the counting of features was made 
with htseq-count (v0.5.3p9) against the mirbase 19 annotation.  
Linear Models for Microarray Analysis (LIMMA) with the voom function 119 were used to find 
differentially overrepresented miRNAs in RISC samples of DM1 patients vs controls. In parallel, 
long RNAs differentially present in RISC IP complex of DM1 vs Healthy patients were identified 
using LIMMA/voom. In order to find miRNAs predicted targets, miRtrail software was used 
(http://mirtrail.bioinf.uni-sb.de/upload.php).  
The gene ontology analysis was performed using WebGestalt (http://www.webgestalt.org) software, 
considering only mRNAs with a stastically significant differential expression between the two groups.  
 
RNA sequencing validation by qPCR 
Input and IP RNAs were retro-transcribed with Taqman microRNA RT kit (Life technologies) and 
Ovation qPCR system (Nugen) to obtain cDNA for miRNAs and mRNAs expression, respectively. 
For miRNAs RT, 10 ng of input RNA and 0.5 µl of IP RNA were retro-transcribed on Thermal 
Cyclers (Bio-Rad), using Taqman microRNA specific assays.  
The cDNA amplification was performed by Taqman Fast 2x PCR Master Mix (Life technologies) on 
Applied biosystems 7900HT Fast Real-time PCR system or on StepOne Plus Real-time PCR system 
(Thermo Fisher Scientific). For mRNAs RT, 20 ng of input RNA and 2 µl of IP RNA were used. The 
cDNA amplification was performed by SybR Green Master Mix (Life technologies) and genes 
specific primers (Table 1).  
The oligos were designed using Integrative Genomics viewer (IGV) 120, UCSC Genome Browser 
(http://genome.ucsc.edu) and Primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast). All 
qPCR measurements were performed in triplicate, and miR-181a and RPL23 were used as 






Table 1. Primer sequences used for RNA-sequencing validation. 
GENE NAME PRIMER FORWARD PRIMER REVERSE 
ACTC1 TCTGTCCACCTTCCAGCAAA TGAGGGAAGGTGGTTTGGAA 
ASB2 TGGGCCACGTCTTCATCTTA AAACCTCTATTCCTGGGGCC 
COL21A1 CCTGTTGTTCGGTGTTGTGA AGGCATACAACAAACATTCCGA 
ERBB3 ATGTCCATTATGCCCGCCTA ACCTGGGAGAGAGAGGGAAT 
FST GCTGTGCCCTGACAGTAAGT GTAGCACACCTGAGGAGCAG 
MYBPH TCAAACTCCAGAGATGCCCA CCCTTGAGCCCAGTTAGTCT 
RPL23 TCCGGATTTCCTTGGGTCTT TGTTCAGCCGTCCCTTGATC 
SESN3 CCTTCAGCACCGTACACCTA GTGGCTGGTGATGTTTGGTT 
WEE TGCCTTGTGAATTTGCTGCT AGGAGGGAAAGGGTGCATTT 
 
Cells culture, myotubes differentiation and characterization 
Immortalized fibroblasts derived from adult patients (DM1, CTR,) were obtained in collaboration 
with Dr. Germana Falcone laboratory (National Research Council, Rome-Italy). The cell lines were 
inducible for MyoD under the control of estrogen receptor. The growing medium was constituted by 
DMEM High glucose (Gibco), 15% Fetal Bovine Serum (FBS, Euroclone), L-Glutamin 200x (Sigma-
Aldrich), Penicillin-Streptomycin 100x (Sigma-Aldrich) and Puromycin (0.2 µg/ml, Serva 
Electrophoresis). The differentiation medium was prepared DMEM high glucose without phenol red 
(Gibco), 2% horse serum (Sigma-Aldrich), Insulin (10µg, NovoMix), Estradiol (10^-4 M, Sigma 
Aldrich) and Penicillin-Streptomycin 100x (Sigma-Aldrich) was used. 
 
Cells were grown on 0.5% gelatin (Bio-Rad) and, when 90% of confluency was reached, the growing 
medium was replaced by the differentiation one. After 4 days in the differentiation medium, cells 
have been lysed by home-made lysis buffer: 150mM KCl (Sigma-Aldrich), 25 mM TrisHCl (Sigma-
Aldrich) pH 7.4, 5 mM EDTA (Sigma-Aldrich), 0.5% NP40 (Sigma-Aldrich), 5 mM DTT (Sigma-
Aldrich), 1 mM PMSF (Sigma-Aldrich), Protease Inhibitor Cocktail Kit (100x, Thermo Scientific), 
RNAsin (0.2 U/µl, Merck-Millipore). After lysis, the protocol of Ago2 immunoprecipitation was 
performed, using Pierce™ Protein A/G Magnetic beads (ThermoFisher Scientific) and 5 µg of 




Fluorescent in situ hybridization (FISH) with MBNL1 co-localization, in myotubes coltures 
All reagents used were RNAse free, prepared with distilled water Diethylpyrocarbonate (DEPC) 
treated. Cells were fixed in 2% paraphormaldehyde for 30 min at 4°C. After 5 washings with PBS 1x 
(Gibco) at RT, they were permeabilized by Triton 0.4% in PBS (Gibco) for 5 minutes at RT.  
Then, cells were incubated in the pre-hybridization buffer (40% Formamide and SSC 2x, Sigma 
Aldrich)) for 10 minutes at RT, and then in the hybridization buffer: 40% formamide (Sigma-
Aldrich), SSC 2x (Sigma-Aldrich), 0.02% BSA (Sigma-Aldrich), 67 ng/µl tRNA, 2mM Vanadyl 
ribonuclease complex, 1 ng/µl [CAG]6 probe and DEPC H2O for 2 hours at 37°C in a humid chamber.  
Next, the cells were washed in post-hybridization buffer (40% formamide and SSC 2x) for 30 min at 
65°C, then 3 washes were performed in: SSC 2x for 15 min at 65°C, SSC 1x for 15 min at 65°C and 
SSC 1x for 10 min at RT. Then, cells were incubate with NGS (Normal Goat Serum, Dako) diluted 
1:20 in PBS+2%BSA, for 20 minutes at RT. Subsequently, an overnight incubation with the antibody 
anti-Mbnl1 (1:1000 in PBS +2% BSA, provided by Prof. C.A. Thornton, University of Rochester) 
was performed; then, an anti-rabbit AlexaFluo 488 (1:400 in PBS+2% BSA) was used for 1 hour at 
RT (1:400 in PBS+2%BSA). After 3 washing in PBS 1x for 5 minutes, cells have been incubated 
with DAPI (1:1000 in SSC 20x) for 30 min at RT. Finally, after 5 washing in PBS, samples were 
prepared using Mowiol mounting medium. 
 
Statistics 
Continuous variables are expressed as mean ± standard error (SE) unless indicated differently. The 
box plots represent data divided in quartiles. For group-wise comparisons, Mann–Whitney U test was 
used. The ability to discriminate between the DM1 and control groups was determined by the receiver 
operating characteristic curve, and the area under the curve was calculated. A ROC curve allows to 
visualize the reciprocal relationship between sensitivity (true positive fraction) and specificity (false 
positive fraction) and is an effective method to evaluate the performance of diagnostic tests. The 
calculation of sensitivity and specificity depends on the threshold value used to separate the two 
classes. As the thresholds gets higher, specificity increases and sensitivity decreases; conversely, 
lower threshold levels correspond to decreased specificity and increased sensitivity. 121 The Area 
Under Curve (AUC) is a value of diagnostic accuracy that quantifies the overall ability of the test to 
discriminate between control and diseased individuals. It ranges from totally non-informative (AUC 
= 0.5) to perfect test (AUC = 1) 122,123. 
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Spearman rank correlation was used to compare miRNA levels with clinical characteristics. For 
multiple linear regression, absolute ∆∆Ct were used to study the association between all the scores 
and clinical characteristics. The normality of the scores was assessed through histogram visualization. 
Outliers were identified by Tukey’s test. All tests were performed 2-sided and p≤0.05 was considered 
as statistically significant, except for RNA-sequencing, where results showing a False Discovery Rate 
(FDR) ≤0.1 were considered. For statistical analysis GraphPad Prism v. 7.0 (GraphPad Software Inc.) 







IV.I. CIRCULATING miRNAs AS POTENTIAL DM BIOMARKERS 
 
Plasma miRNA validation in DM1 patients 
Platelet-free plasma samples were harvested from 103 DM1, and 111 age- and sex- matched control 
(CTR) patients, displaying no neuromuscular disorders. DM1 patients presented the typical hallmarks 
of myotonic dystrophy, summarized in table 2 50. Most of the patients were in stage 3 of the disease 
(MIRS score) 114 and the pathological CTG expansions ranged from 65 to 1400.  
Of note, there was no overlap between the patients and controls analyzed in this study and the ones 
analyzed in our previous investigation 108. Total RNA was extracted from plasma samples and 
miRNAs were measured by qPCR.  
For this validation study, we measured miR-133a, miR-193b, miR-191, miR-140-3p, miR-27b, miR-
454, miR-574, miR-885-5p and miR-886-3p, previously described in Perfetti et al. 108, and miR-1, 
miR-206 and miR-133b identified by Koutsoulidou and collaborators 107.  
Normalization is a critical issue in all circulating miRNA studies 125. For this reason, three normalizers 
were used, one exogenous (cel-miR-39) and two endogenous (miR-106a and miR-17-5p). The high 
number of DM1 patients and of miRNAs tested required several qPCR sessions. To make sure to 
have comparable results, we used a reference sample obtained by pooling a fraction of all control 
preparations. Given that normalization is a fundamental step in this kind of studies, and in order to 
obtain maximum specificity, were considered as validated only those miRNAs that displayed 
significant differences after normalization with all the following normalizer combinations: 1) the 
average of cel-miR-39, miR-106a and miR-17-5p (Figure 3); 2) exogenous cel-miR-39 only (Figure 
4a); 3) the average of the two endogenous miRNAs, miR-106a and miR-17-5p (Figure 4b). In this 
way, it was confirmed that in DM1, 8 miRNAs out of 12 were deregulated.  
Particularly, miR-27b was the only one down-modulated, while miR-133a,-133b,-140-3p, -454 and-
574 were up-regulated. It is worth noting that values obtained with all normalization criteria were 
very similar, confirming data robustness. 
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Table 2. Clinical characteristics of DM1, DM2 and control patients recruited for blood 
samplings. 






Age at sampling (average ± se) 44.1 ± 1.3 54.7 ± 2.7 43.0±1.0 
Age of onset (average ± se) 25.9 ± 1.3 41.5 ± 2.4 NR 
Sex (male/female) 58/45 13/17 51/60 
MRC megascore (average ± se) 118.6 ± 1.9 143.5 ± 1.4 150.0±0.0 
Myotonia (% of patients) 87 54 0 
Glucose (normal values: 70-110 mg/dl) 88.7 ± 1.2 112.3 ± 13.6 90.3±1.3 
Cholesterol (normal values: <200 mg/dl) 212.0 ± 6.7 230.1± 9.6 204.0±6.0 
CK 














Arrhythmia (% of patients) 38 12 0 
Cataract (% of patients) 56 32 0 
ECG-QRS duration 
(normal values: 60-110 ms) 
103.5±4.3 99.1±4.5 NA 
Number of CTG repeats (range) 484.0 ± 27.6        
(65-1400) 
NA NA 
Stage of disease (range 1-5) 
(% of patients at each stage) 
Stage 1: 5 NR NR 
Stage 2: 29 NR 
Stage 3: 34 NR 
Stage 4: 28 NR 
Stage 5: 3 NR 







Figure 3 Validation of plasma miRNAs in DM1 patients using all 3 normalizers. The bar graph represents mean 
values of the indicated miRNAs in plasma of DM1 patients compared to controls (CTR). Average values of cel-miR-39, 
miR106a and 17-5p were used for normalization (DM1 n=103, CTR n= 111; **** p<0.0001, * p<0.05). 
Figure 4 Plasma signature with different normalization criteria. The bar graphs represent the significantly 
modulated miRNAs using different combinations of the 3 normalizers comparing DM1 versus CTR patients. (DM1 
n=103, CTR n=111; **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05). a) Average values of cel-miR-39 were used 
for normalization. b) Average values of miR106a and 17-5p were used for normalization. 
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Deregulated plasma miRNA signature accurately identify DM1 patients 
To test the accuracy of deregulated miRNAs, Receiver Operator Characteristics (ROC) curves were 
calculated for each plasma miRNA found differentially expressed in DM1. In this way, it was found 
that miR-133b (table 3) displayed the highest Area Under Curve (AUC=0.82), and all myomiRs 
exhibited similar AUCs (from 0.79 to 0.81, table 3). Non-myogenic miRNAs, instead, presented 
lower but still significant values (from 0.58 to 0.81, table 3). 
 
Table 3. Area under curves (AUC) of each validated plasma miRNAs in DM1 compared to controls. 
microRNA AUC Confidence Interval 
(C.I.) 
p-value 
miR-133b 0.82 0.76-0.87 <0.0001 
miR-1 0.81 0.74-0.86 <0.0001 
miR-133a 0.80 0.74-0.86 <0.0001 
miR-206 0.79 0.73-0.85 <0.0001 
miR-574 0.71 0.63-0.68 <0.0001 
miR-454 0.70 0.62-0.76 <0.0001 
miR-140-3p 0.69 0.61-0.76 <0.0001 
miR-27b 0.58 0.50-0.66 <0.05 
 
In order to test whether combining the values of different miRNAs, allowed even better performances, 
three scores were calculated. The first, named “DM1-miRNA score”, was obtained averaging the fold 
changes obtained from all miRNAs, as described also in 108 (Figure 5); the second is the “myomiRs 
score”, obtained averaging the fold changes of myomiRs only (i.e. miR-1, -133a, -133b and miR-
206) (Figure 6). The last one, miR-133a/b score, was obtained averaging the fold changes of miR-
133a and b (Figure 7). As shown in table 3 all scores present AUCs better than miR-133b alone, with 
AUC of 0.85 for DM1-miRNA score (Figure 5), 0.87 for the myomiR score (Figure 6) and 0.86 for 
miR-133a/b score (Figure 7). 
In particular, considering a cut-off value of 2.55, sensitivities of 81.6%, 82.3%, and 82.5% as well as 
specificities of 70.3%, 71.2% and 71.2% were observed for the DM1-miRNAs score, the myomiR 




Figure 5. DM1-miRNA score validation as DM1 biomarker. The DM1-miRNA score was calculated averaging the fold changes 
of miR-1, -133a, -133b, -140-3p, -206, -27b, -454 and -574 in the plasma of DM1 and controls (DM1 n=103, CTR n=111). a) Box 
plot of DM1-miRNA score levels in the plasma of DM1 and controls (CTR; **** p<0.0001). b) ROC curve illustrating sensitivity 
and specificity of the DM1-miRNA score in discriminating healthy from diseased patients. c) Spearman’s inverse correlation between 
the DM1-miRNA score and muscle strength measured by MRC megascore. d) Spearman’s direct correlation between the DM1-
miRNA score and CK plasma levels. 
Figure 6. myomiR score validation as DM1 biomarker. The myomiR score was calculated averaging the fold 
changes of miR-1, -133a, -133b, and -206 in the plasma of DM1 and controls (DM1 n=103, CTR n=111). A) Box 
plot of myomiR score levels in the plasma of DM1 and controls (CTR; **** p<0.0001). B) ROC curve illustrating 
sensitivity and specificity of the myomiR score in discriminating healthy from diseased patients. C) Spearman’s 
inverse correlation between the myomiR score and muscle strength measured by MRC megascore. D) Spearman’s 




Finally, we also found that, using different normalization procedures, similar AUC values were 
obtained for all scores, confirming the robustness of the data (Table 3). 
 
Table 5. Are under curves (AUC) obtained with different normalization criteria  
 Data normalized vs 
 Average 
(miR-106a, -17, -39) 
miR-39 miR-106a miR-17 
Average 
(miR-106a, -17) 






























All results have p-value<0.0001. 
Figure 7. miR-133 a/b score validation as DM1 biomarker. The miR-133a/b score was calculated averaging the fold 
changes of miRNA-133a and -133b in the plasma of DM1 and controls (DM1 n=103, CTR n=111). A) Box plot of 
miR-133a/b score levels in the plasma of DM1 and controls (CTR; **** p<0.0001). B) ROC curve illustrating 
sensitivity and specificity of the miR-133a/b score in discriminating healthy from diseased patients. C) Spearman’s 
inverse correlation between the miR-133a/b score and muscle strength measured by MRC megascore. D) Spearman’s 
direct correlation between the miR-133a/b score and CK plasma levels 
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DM1-deregulated miRNAs are similarly modulated in DM2 patients 
In order to assess whether the miRNA deregulation found in DM1 patients was also observed in DM2 
patients, the plasma of 30 DM2 patients (Table 2) and 30 age and sex matched control subjects was 
assayed. Figure 8 shows that, with the exception of miR-27b, all the other miRNAs were significantly 
increased, further confirming the similarity of the two DM diseases. 
Next, the differentiating value of the identified miRNAs were tested in DM2 patients, calculating the 
same scores as for DM1, keeping out miR-27b. It was found that all three scores efficiently 




Figure 8. Validation of plasma miRNAs in DM2. The bar graph represents mean values of the indicated miRNAs in 
plasma of DM2 patients compared to controls (CTR). Average values of cel-miR-39, miR106a and 17-5p were used for 




Plasma miRNAs correlation with clinical relevant parameters 
Taking the results of deregulated plasma miRNAs, correlations with interesting clinical parameters 
have been found. Particularly, analyzing all subjects, miR-133b levels (Figure 10a) and all three 
scores displayed a weak, but still significant correlation with muscle strength (MRC, figures 5, 6 and 
7 c) and a correlation with CK levels (Figures 5, 6 and 7 d and figure 10 b). One of possible limitation 
of the latter result is that exercise in the days before testing was not recorded.  
 
 
Figure 10. Correlation between miR-133b and some clinical parameters. A) Spearman’s inverse correlation between 
miR-133b fold changes and skeletal muscle strength and B) direct correlation with plasma levels of creatine kinase (DM1, 
n=103, CTR, n=111).   
Figure 9. ROC curves of DM2 compared to healthy subjects. Specificity and sensibility of a) DM2-miRNA score, 
myomiR score (b) and miR-133a/b score (c) (DM2, n=30; CTR, n=30). 
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Moreover, we also found that miR-133b levels were significantly higher in female DM1 patients 
compared to DM1 males, while no difference was observed in control subjects (Figure 11). This 
difference was present with all three normalization procedures.  
 
Next, to better investigate the relationship between clinically relevant variables in DM1 patients that 
were most affected by disease, i.e. with MIRS >2, a multiple linear regression was performed 
analyzing CK values, age of onset, number of triplet expansions and muscle strength. Statistically 
significant associations are reported in table 6. We identified the association of muscle strength with 
miR-133b levels and all three scores. Moreover, CK values were associated to myomiR-score and 
miR-133a/b score. We can conclude that all the identified scores display good combinations of 
sensitivity, specificity and correlation with clinically relevant features.  
Considering the minimization of the number of assays as an important parameter for the 
transferability to the clinical practice, also a miR-133a/b score obtained using only the two internal 
normalizers (Table 5) displayed features very similar to these obtained using the three normalizers 
(Figure 7b).  
 
Figure 11. miR-133b plasma levels are higher in DM1 female population. Box and whiskers represents minimum and 
maximum values (DM1, n=103, CTR, n=111, ** p<0.01, ns = not statistically significant). 
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Table 6. Multiple regression analysis, DM1 patients with stage of disease higher than 2 
 
  
SCORE PARAMETERS COEFFICIENT STD 
ERROR 
p-value 
DM1-miRNA ΔMRCa  0.036 0.013 0.011 
myomiR ΔMRC  0.042 0.015 0.007 
CK 0.004 0.002 0.033 
miR133a/b ΔMRC 0.038 0.014 0.011 
miR-133b ΔMRC 0.059 0.019 0.005 
CK 0.005 0.002 0.035 
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IV.II. EXPRESSION PROFILING OF RISC-ASSOCIATED SMALL RNAs 






Setting up of the experimental conditions 
Conditions for Ago2 immunoprecipitations had been set up in the past by our group 97, but in cells of 
mouse origin. In order to set up the Ago2 immunoprecipitation protocol in human muscle biopsies, 
tissue lysates were immunoprecipitated with two Ago2 antibodies, and analyzed for miRNA co-
precipitation. miR-1 and miR-221 were readily detectable in immunoprecipitates obtained with both 
Ago2 antibodies(Figure 13a). Next, mRNAs enrichment was also tested in Millipore RISC-IP 
samples. Figure 13 b shows that indeed both, p27 and GAPDH mRNAs were easily detectable in 
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RNA sequencing pilot experiment 
RNA derived from immunoprecipitated samples is very low abundant (50-100 ng/sample), and RNA-
sequencing conditions from low RNA amounts had already been set up for long RNAs, but not for 
small RNAs (miRNAs). Thus, a pilot small RNA sequencing experiment was performed, using either 
1 µg of total RNA, as indicated by manufacturer’s instructions, or 50 ng. For this pilot experiment, 
total RNA was derived from skeletal muscle biopsies of one control and one DM1 patient. 
 
Using an adapted protocol consisting in a higher number of PCR cycles, thus producing more 
abundant small RNA bands, we managed to produce good quality libraries. The sequencing of these 
Figure 12. Enrichment of miRNAs and mRNAs in RISC-IP immunoprecipitations. The tissue lysate derived from 
one skeletal muscle biopsy was mmunoprecipitated by Millipore or Sigma antibodies and separated by magnetic beads. 
Next, the co-immunoprecipitated RNAs were extracted and analyzed by qPCR a) The levels of miR-1 and miR-221 were 
normalized against U6 RNA. b) Specific enrichment of p27, GAPDH, and c-Fos mRNAs in Ago2 Millipore IP, 




libraries yielded very similar results in terms of small RNAs identified and quantified to what 
obtained with the recommended amount of starting material (1 µg) (Figure 13). 
 
Then, it was concluded that 50 ng of RNA were sufficient to perform small RNA sequencing. 
 
RNA sequencing of small RNAs and mRNAs in DM1 patients. 
Duplicate biopsies from biceps muscles of 3 healthy individuals and 3 DM1 patients were used to 
extract either total (Input) RNA or RNA derived from RISC-IPs. The RNAs quality control was 
performed with Input samples, using Bioanalyzer, which confirmed that all RIN values were > 7. 
 
Figure 13. Setting the small RNAs library preparation protocol. Libraries prepared from 50 ng and from 1µg of 
RNA yielded similar results. Low represented small RNA were amplified at higher levels using 50 ng likely reflecting 
the effects of a higher number of PCR cycles. The reads mapping to medium and high abundance small RNAs were  





RNA sequencing results displayed high quality and the expected distribution of mRNAs and small 
RNAs reads (Figure 14)  
Moreover, the principal component analysis showed the expected separation between DM1 and 
control samples, both for long RNAs (mRNAs) and for small RNAs (miRNAs) (Fig.15) 
Figure 15. Principal component analysis clearly separate the two groups. Samples distribution after long RNAs (a) 
and small RNAs (b) sequencing. 
Figure 14. Quality control of smallRNA sequencing libraries. After trimming of the adapters, sequences displayed 
good quality (a) and a size distribution (b) showing enrichment in microRNAs (21-22 bp) and piRNAs (32 bp). 
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In order to highlight differentially expressed mRNAs and miRNAs in the RISC-IP samples of DM1 
compared to control patients, a False Discovery Rate (FDR) <0.1 was considered. Among 12796 
mRNAs detected by sequencing, 101 genes were found significantly deregulated in DM1 RISC 
complexes (Figure 16), while, in miRNAs analysis, among 208 detected, 37 resulted differently 
represented in IPs from DM1 patients (Figure 17). Moreover, by looking at miRNA predicted targets 
using miRTrail 126 amongst the mRNAs and the differentially expressed miRNAs in RISC complexes, 
we found several miRNA-mRNA couples deregulated in DM vs healthy muscle samples (table 7). 
Both correlations (miRNA up and target up or viceversa) and anticorrelations (miRNA up and target 
down) were found. Both correlation and anticorrelation can be functionally explained, depending on 
the regulatory mechanisms exerted by the RISC-associated miRNAs vs their target transcripts 
(translational control or mRNA degradation) 72. 
 
Figure 16. Volcano plot of differentially expressed mRNAs revealed by RNA-sequencing. Red dots represent 






Table 7. DM1 RISC-enriched miRNAs associated to their differentially expressed mRNA 
targets.  
miRNAs Target mRNAs 
miR-15a SRPR; ACTC1; WEE1 
miR-155 COL21A1; WEE1; TSPAN13; SESN3; FHOD1; LRP1B; CFH 
miR-22 ERBB3 
miR-29c MYBPH; WDR47; DDAH1; CSPG4; ASB2 
miR-222 TSPAN13; SLC35F1;MYLK2 
miR-381 LRP1B; DUSP3; LEPREL1 
miR-411 FST; GPSM2 
Red and green colors indicate increased and decreased expression in DM1 RISC-IP samples compared to controls, 
respectively (FDR<0.1). 
Figure 17. MA-plot of differentially expressed miRNAs in DM1, revealed by RNA-seq. Red dots represent 
statistically significant data (FDR<0.1). (DM1, n=3; CTR, n=3). 
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RNA-sequencing results showed that amongst the most abundant miRNAs present in DM1 RISC 
complexes we could find miR-222, miR-381, miR-146b and miR-411, previously found involved in 
skeletal muscle physiopathology (Greco, 2009, Greco 2012, Khanna, 2014; Harafuji, 2013); among 
mRNA transcripts, ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3), FST (Follistatin) and ACTC1 
(Actin, Alpha, Cardiac Muscle 1) are deeply involved in skeletal muscle metabolism 127–129.  
 
Gene ontology analysis 
Gene ontology analysis of the mRNAs dysregulated in DM1 was performed with WebGestalt 
software, using different enrichment analysis. KEGG analysis showed that among the top pathways 
represented by differentially expressed genes (FDR<0.1), there were glycolysis and gluconeogenesis 
(Figure 18), two important biological processes altered in DM 130.  
Moreover, in the Pathways commons database, interestingly, the mRNAs dysregulated in DM1 were 
found enriched also in the insulin and Akt pathways, which are involved in DM pathogenesis (Figure 
19) 1,131.  
Figure 18. Enrichment analysis with KEGG pathways. Top 10 pathways enriched by differentially expressed 






RNA sequencing validation in skeletal muscle tissue 
In order to validate miRNAs and mRNAs found differentially expressed in RISC-IP samples by RNA 
sequencing, qPCR was used. To select the miRNAs and mRNAs to validate, the following criteria 
were used: regarding mRNAs, only genes that were target of differentially expressed miRNAs, 
presenting an FDR≤0.05 were considered; on the other hand, only those miRNAs that were 
significantly modulated in RISC complexes of DM1 and at the same time had modulated targets, 
were taken into consideration for validation analysis. In this way, 8 mRNAs and 7 miRNAs (Table 
8) were selected for qPCR assays, in RISC immunoprecipitations from skeletal muscles of 8 DM1 
and 8 CTRL samples.  
 
Table 8. RNA-sequencing results about selected differentially expressed mRNAs and miRNAs in RISC-IP samples. 
Modulation 
(DM1 vs CTR) 
mRNAs miRNAs 
UP 
ACTC1, FST, ERBB3, WEE, 
SESN3, MYBPH, COL21A1 
miR-381, miR-411, miR-222, 
miR-155,  
DOWN ASB2 miR-22, miR-29c, miR-15a 
Figure 19. Enrichment analysis with Pathways Commons database. Top 10 pathways enriched by differentially 
expressed mRNAs found in RISC complexes of DM1 compared to control patients (DM1, n=3; CTR, n=3, FDR<0.1) 
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Figure 20 shows that 6 mRNAs were confirmed to be differentially expressed in DM1 patients 
compared to healthy subjects. In particular, SESN3 (Sestrin 3), ACTC1 (Actin, Alpha, Cardiac 
muscle I), FST (Follistatin), WEE1 (WEE1 G2 Checkpoint kinase), ERBB3 (Erb-B2 Receptor 
Tyrosine kinase 3) were up-regulated (Figure 21 a, b, d, e and f) in RISC complexes of DM1 and only 
one, ASB2 (Ankyrin Repeat And SOCS Box Containing 2), down-modulated (Figure 20 c). 
Moreover, these results were also analyzed in Input RNAs, confirming that their enrichment or 
depletion in RISC complexes was not due to a similar modulation in total RNAs (Figure 21), but 
rather the modulation in total RNA was often absent or in the opposite direction. 
RNA-sequencing results about selected miRNAs showed that in RISC-IP samples, 4 were enriched 
and 3 decreased in DM1 vs healthy subjects (Table 8). In particular, miR-381, 411, -222 and -155 
were found to be up-regulated in DM1, while miR-22, -29c and -15a were down modulated. 
MiRNAs qPCR validation showed similar results found in RNA-sequencing, for all miRNAs. 
However, statistical significance was not reached in all cases, possibly due to low levels and 














Figure 20. RNA-sequencing validation of mRNA transcripts in skeletal muscle tissue. qPCR validation of 
mRNA targets in DM1 vs healthy subjects. Data obtained in total (Input) RNA and RISC-IP samples are shown. 
SESN3 (A), ACTC1 (B), FST (D), WEE (E) AND ERBB3 (F) were enriched in IP samples of DM1, while ASB2 













RNA sequencing validation in vitro 
Given that the number of functional experiments that can be performed using skeletal muscle tissue 
is limited, we adopted a cell model of immortalized skin fibroblasts induced to differentiate into 
myotubes by myoD expression. For this reason, we took advantage of cells derived from adult 
patients, developed in close collaboration with the group of Dr. Germana Falcone (National Research 
Council, Monterotondo Scalo- Rome). Fibroblasts derived from DM1 patients and controls were 
immortalized by Telomerase expression and transduced with estrogen-inducible MyoD. After 
reaching the confluency (Figure 22), DM1 and CTR cells were induced to differentiate (Figure 23) 
and after 3 days in differentiation medium, they were treated to immunoprecipitate Ago2 protein, 





Figure 21. Heat map of miRNAs modulation in skeletal muscle tissue. Comparison 
between RNA-seq results (DM1, n=3; CTR, n=3) and qPCR validation (DM1, n= 7; 
CTR, n=6) in RISC-IP samples of DM1 compared to control subjects. Data are 













Figure 22: Immortalized fibroblasts derived from DM1 and control patients Confluent fibroblasts in control (a) 
and in DM1 (c) in proliferative medium (phase-contrast microscope, magnification 5X);  
Figure 23: Immortalized fibroblasts derived from DM1 and control patients, induced to differentiate in 




In parallel cultures, an in situ hybridization was performed to verify the presence of ribonuclear 
inclusions (Figure 24, panels b-e) and their co-localization with MBNL1 protein (Figure 24, panels 




According to data obtained in skeletal muscle biopsies, we found that miR-411 and FST mRNA were 






Figure 24: In situ hybridization of myotubes from DM1 patients, and co-localization with MBNL1 protein. 









Figure 25: RISC-IP assays of cultured myotubes confirm some miRNA/mRNA couples found deregulated in 
DM1 skeletal muscles. RNA was isolated from RISC complexes derived from DM1 and CTR cultured myotubes. 
miRNAs and mRNAs were measured by qPCR. miR-411 and -29c were normalized against miR-181a, FST and 





Although DM it is the most frequent muscular dystrophy in adulthood, the complex mechanism 
which gives rise to this disease is not well understood; moreover, no specific treatments are available 
and, to date, only the invasive method of skeletal muscle biopsy allows to accurately monitor the 
disease progression 5,11.  
microRNAs have a fundamental role in the post-transcriptional regulation of several mRNA 
transcripts, associated to the protein effector complex RISC. Furthermore, they are not only present 
in tissues, but also in body fluids, where they are very stable and could participate to the intercellular 
communication or they should reflect the state of a specific organ.  
Even if the research on miRNA has been booming in the last few years, miRNAs potential as 
therapeutic targets and as disease biomarkers in DM is still not clear. Some reports on miRNAs 
dysregulation in DM have been published 95,96. However, in most circumstances, it has not been 
established whether these events lead to dysregulation of their miRNA targets, and to which extent. 
Moreover, some conflicting results are also present 95,96,132 
On the other hand, the studies about circulating miRNAs in plasma or sera of DM1 patients lack 
of power and of reproducibility, because of the small groups considered and the absence of a 
standardized normalization method 107,108. 
In this study, both tissue and plasma miRNAs were studied with different approaches. 
In particular, in the first part, we measured the same plasma miRNAs previously found deregulated 
in plasma or serum of DM1 patients in a larger and independent group, in order to corroborate or 
disprove the existing data. Here we analyzed more than 200 subjects between DM1 patients and 
controls. Albeit still limited in size, this already represents a big step forward compared to similar 
studies performed in rare diseases. Additionally, an accurate normalization method and stringent 
inclusion criteria were adopted. This approach allowed us to validate eight previously identified 
miRNAs, whereas four miRNAs were not confirmed, proving the importance of an accurate 
validation procedure. It is also worth noting that one of the RNA that were not confirmed, miR-886, 
is not even properly a miRNA, since it is identical to a fragment of Vault RNA 2 (VTRNA2) 133, 
further supporting the superior performances of miRNAs as biomarkers. Finally, it is also worth 
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noting that small studies also display low sensitivity. Indeed, several myomiR identified by 
Koutsoulidou, et al. 107 escaped identification in our previous study. 
In this work, we validated the myomiR miR-1, 133a,-133b and -206 as increased in the plasma of 
DM1 patients. Both miR-133a/b and myomiR scores correlated, although weakly, with clinical 
parameters of muscle involvement, supporting the hypothesis that myomiR dysregulation in the 
plasma of DM1 patients is specifically related to mechanisms of muscle damage. Whether this was 
due to passive release from damaged myofibers, it is not known. However, unlike Duchenne muscle 
dystrophy, necrosis is not a DM1 disease hallmark and this increase might be due, at least in part, to 
active mechanisms. Interestingly, while myomiR levels are not modulated in DM1 skeletal muscle 
biopsies, their intracellular distribution is aberrant 96, possibly leading also to increased extracellular 
release.  
Also interesting is the fact that miR-133b elevation was particularly prominent in DM1 female 
patients. While the reason for this gender difference is unknown, it is not surprising since gender is 
emerging as an important factor influencing DM1 clinical profile 134. Of note, it has been found that 
miR-133b stimulates ovarian estradiol synthesis 135. Whether this is related to the endocrinological 
abnormalities observed in DM1 patients remains to be elucidated. 
 Other non muscle-specific miRNAs, namely miR-140, -27b, -454 and -574 were also validated as 
deregulated in DM1 plasma. Indeed, since DM1 is a multisystemic disorder, it is possible that the 
tissue of origin of these miRNAs might not be the skeletal muscle. According to the human miRNA 
tissue atlas (https://ccb-web.cs.uni-saarland.de/tissueatlas), they are expressed, to different extent in 
multiple tissues, including brain, nerve, spinal cord, thyroid and epididymis. Thus, the plasma levels 
of these miRNAs may reflect the global clinical state of the patient, rather than that of a specific 
tissue.  
Notably, the new plasma signature has also been confirmed in a small group of DM2 patients. 
While confirmatory studies in larger patient groups are necessary, this finding suggests that similar 
mechanisms underpinning miRNA release in the blood might be shared by DM1 and 2. 
 
In skeletal muscle biopsies we have adopted an experimental strategy in order to identify both 
miRNAs effectively active and deregulated in DM1 patients, and their respective mRNA targets. 
Using a combination of RNA-sequencing, Ago2 protein immunoprecipitation, target prediction 
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algorithms and qPCR assays, we have found the dysregulation of very interesting miRNA/mRNA 
couples in DM1 patients.  
The couple miR-411/FST , found enriched in RISC complex of DM1, is particularly worthy of 
note because both the miRNA and its target are known to be involved in the regulation of skeletal 
muscle mass. Indeed, miR-411 it’s up-regulated in Facioscapulohumeral muscular dystrophy (FSHD) 
myoblasts, where it is localized in cytoplasm and regulates the suppression of myogenic factors like 
MyoD and Myogenin 136, affecting myogenesis. Interestingly, miR-411 increase was also confirmed 
in DM1 myogenic cells cultured in vitro. 
 
FST is an inhibitor of TGF-β superfamily ligands, which usually repress skeletal muscle growth 
128. Overexpression of FST promotes skeletal muscle hypertrophy in primates 137, and for muscles of 
mdx mice- models of Duchenne and Becker muscular dystrophies- was found ameliorative 138. 
Moreover, it has been demonstrated that administration of FST to muscles at the time of tenotomy, 
largely prevented the loss of muscle mass, confirming the importance of FST in the regulation of 
muscle integrity 128.  
Given that FST is enriched in the RISC complex of DM1 patients together with its regulatory 
miRNA, miR-411, we should speculate that the translation of FST is much more impaired in DM1, 
resulting in a protein decrease, possibly contributing to the loss of muscle mass and atrophy, 
characterizing DM1 1. It is also important to underline that, on the contrary of FST, ASB2, controlled 
by miR-29c, is less associated to Ago2 protein in DM1 patients, and so its translation is probably 
more efficient in the diseased muscles. Very recently, Davey end colleagues 139 demonstrated that 
overexpression of FST leads to the down-regulation of Asb2 protein, especially in young adult mouse 
muscles, and this is necessary for the maximal hypertrophic response to FST 139. In the same work, it 
has been elucidated that expression of ASB2 resulted in a progressive muscle atrophy, indicating 
ASB2 as a negative regulator of basal muscle mass 139.  
These findings suggest that a mechanism involving FST/ASB2 dysregulation might be involved 
in one of the hallmark of DM, the skeletal muscle atrophy 1. Further studies aimed at directly testing 
this hypothesis are granted. 
Another important miRNA which is more efficiently recruited in RISC complexes of DM1 patients 
is miR-222. Previous work of our group found this miRNA to be modulated during myogenesis 
together with miR-221, with an important role in the progression from myoblasts to myocytes and in 
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the reaching of a fully differentiated phenotype 140. Moreover, very recently, our group further 
elucidated the role of miR-222 in myogenesis, highlighting that, repressing Rbm24 transcript, miR-
222 can indirectly regulate the alternative splicing of many muscle-specific transcripts 97. Thus, miR-
222 enrichment in RISC complexes of DM1 patients is particularly intriguing, suggesting its 
implication in the skeletal muscle dysfunction and aberrant splicing characterizing DM1. 
ERBB3 is essential in many different cell types, because it is implicated in cell growth, apoptosis 
and differentiation 127. In vitro, ErbB3 along with its ligand Neuregulin, have different effects on 
myogenic progression. Neuregulin inhibits myogenin expression in proliferating myoblasts 141, while 
in myotubes promotes differentiation and muscle growth 142,143. The fact that ERBB3 was found 
enriched in RISC complexes of DM1 patients, suggests its repression in diseased muscles, 
corroborating the hypothesis that in DM, most pathways involved in muscle mass regulation are 
impaired.  
WEE1 is a tyrosine kinase that phosphorylates cdc25 at the G2/M checkpoint and prevents the 
progression to mitosis 144. Even if its role in the skeletal muscles is not well understood, WEE1 has 
been found to be involved in myoblast cells death/growth arrest induced by hypoxia 145, which impairs 
myogenic differentiation 146,147.  
ACTC1 mRNA is also increased in RISC complexes derived from muscles of DM1 patients. The 
multigene family of actins provides the major structural component of myofibril thin filament and 
both the skeletal muscle (ACTA1) and the cardiac (ACTC1) actin isoforms are expressed in skeletal 
muscles . 148. Although ACTC1 is generally less abundant than ACTA1 in mature skeletal muscles, 
it has been found to be highly increased during muscle regeneration, characterizing activated satellite 
cells and regenerating myofibers 129. Its RISC enrichment could suggests ACTC1 repression I DM1, 
which might be related to a reduced proliferative capacity of satellite cells, observed in DM1 149.  
Bioinformatic analysis of the pathways and functions associated to the deregulated genes also 
provided interesting indications. Indeed, gene ontology showed that the most represented categories 
were related to glucose metabolism and gluconeogenesis, which are two important pathways involved 
in DM pathogenesis. Indeed, in normal conditions, skeletal muscle requires an efficient glucose 
metabolism for its high-energy demand, in DM, the aberrant splicing of IR and pyruvate kinase M2 
(PKM2) disrupts glucose homeostasis 45,130. The fact that many genes differentially expressed in 
RISC complex of DM1 patients are involved in these pathways, seems to suggest that also miRNA-
based mechanisms, besides the alteration of alternative splicing, might be implicated in the complex 
regulation of glucose metabolism. 
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One of the transcripts involved in glucose metabolism is SESN3, up-regulated in RISC complexes 
of DM1 patients. It is known that all members of Sestrins family, SESN1, 2 and 3, in humans are 
involved in the signal transduction through AMPK (AMP-activated protein kinase) and mTOR 
(mammalian target of rapamycin), which are cellular energy sensors responding to control 
metabolism in insulin-sensitive tissues 150. However, it has also been discovered that SESN3 
knockdown in cultured human myotubes does not impact insulin sensitivity, but increases myostatin 





VI. CONCLUSIONS AND FUTURE 
DEVELOPMENTS 
In the plasma of DM1 patients, three potentially useful miRNA scores were identified: the most 
simple is the miR133a/b that consists of only 2 miRNAs, facilitating the potential transfer to the 
clinical practice. On the other side, the DM1-miRNA score, constituted by 8 miRNAs, is more 
complex, but displays better correlation with clinically relevant parameters. Moreover, it is not 
constituted only by myomiRs, that have been found to be deregulated in other dystrophies as well 
105,106. Thus, it holds the potential to be more DM-specific. However, this remains to be determined 
experimentally. Also important will be a longitudinal study, to ascertain how the identified scores 
change over time during DM1 disease evolution. 
Very important for the potential transferability to the clinics will be the development of absolute 
quantification assays and the identification of reference values. 
As a final remark, a humoral biomarker that may facilitate disease state monitoring of the patients 
using a minimally invasive procedure might be particularly useful considering perspective therapeutic 
options, as indicated by ongoing clinical trials (NCT02312011, NCT01406873). 
 
In the skeletal muscles we identified Ago2-associated miRNAs and mRNA targets dysregulated 
in DM1. These miRNA/mRNA couples seem to be mainly involved in the regulation of muscle mass 
and in glucose metabolism. Since muscle atrophy and insulin resistance are two main features of DM, 
these observations might be of potential therapeutic usefulness.  
Future experiment may allow to ascertain the functional role of the identified miRNA/mRNA 
couples in skeletal muscle physio-pathology. To this aim, the identification of some of these 
miRNA/target mRNA dysregulations in DM1 myogenic cells cultured in vitro, paves the way for 
future functional experiments.  
Also important will be assessing the relevance of the identified miRNA/mRNA couples in DM. In 
this respect, it will be crucial to determine how profound the impact of miRNA deregulations is on 
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